TABLE 2.
Top 30 HIV-1 NRTI resistance patterns in 4,089 sequences from 3,550 persons with NRTI resistance, 1997 to 2003
| Mutation pattern | No. (%) of sequencesa | No. of personsa | Cumulative % | Susceptibility to drug (foldn)b
|
|||||
|---|---|---|---|---|---|---|---|---|---|
| ZDV | D4T | TDF | ABC | DDI | 3TC | ||||
| M184V | 710 (17.4) | 609 | 17.4 | 0.530 | 0.832 | 0.64 | 3.132 | 1.530 | >20031 |
| M41L, M184V, T215Y | 156 (3.8) | 125 | 21.2 | 5.513 | 1.513 | 1.03 | 5.115 | 1.513 | >20013 |
| M41L, M184V, L210W, T215Y | 100 (2.4) | 88 | 23.7 | 159 | 1.89 | 1.24 | 6.110 | 1.79 | >2009 |
| M41L, T215Y | 82 (2.0) | 71 | 25.7 | 123 | 1.83 | 2.63 | 1.23 | 2.03 | |
| D67N, K70R, M184V, K219Q | 79 (1.9) | 61 | 27.6 | 7.52 | 1.42 | 1.61 | 5.22 | 1.62 | >2002 |
| K70R, M184V | 65 (1.6) | 55 | 29.2 | 1.11 | 0.71 | 2.21 | 1.51 | >2002 | |
| M41L, L210W, T215Y | 56 (1.4) | 48 | 30.6 | 2632 | 2.12 | 3.42 | 3.02 | 1.22 | 1.82 |
| M184V, T215Y | 50 (1.2) | 42 | 31.8 | 1.14 | 1.24 | 0.52 | 5.24 | 1.94 | >2004 |
| V118I | 48 (1.2) | 44 | 33.0 | 1.01 | 0.91 | 1.01 | 1.11 | 1.01 | |
| T215Y | 38 (0.9) | 31 | 33.9 | 117 | 1.57 | 1.46 | 1.37 | 1.17 | 1.77 |
| M41L, V118I, M184V, L210W, T215Y | 37 (0.9) | 31 | 34.8 | 5.53 | 2.33 | 1.82 | 5.53 | 1.73 | >2003 |
| M41L, D67N, V118I, L210W, T215Y | 35 (0.9) | 30 | 35.6 | 2,4001 | 6.91 | 5.61 | 6.61 | 2.31 | 7.81 |
| L74V, M184V | 33 (0.8) | 31 | 36.5 | 0.31 | 1.01 | 5.32 | 2.61 | >2001 | |
| D67N, K70R, M184V | 32 (0.8) | 27 | 37.2 | 1.12 | 1.02 | 0.71 | 3.02 | 1.32 | >2002 |
| D67N, T69N, K70R, M184V, K219Q | 28 (0.7) | 22 | 37.9 | 7.91 | 2.31 | 7.71 | 1.81 | >2001 | |
| M41L, D67N, M184V, L210W, T215Y | 27 (0.7) | 24 | 38.6 | 306 | 2.66 | 2.12 | 6.45 | 1.96 | >2006 |
| M41L, M184V | 27 (0.7) | 19 | 39.2 | 0.51 | 0.61 | 0.41 | 1.61 | 1.41 | >2001 |
| A62V, M184V | 26 (0.6) | 22 | 39.9 | 0.31 | 0.71 | 0.41 | 3.81 | 1.91 | >2001 |
| M41L, E44D, D67N, V118I, M184V, L210W, T215Y | 25 (0.6) | 20 | 40.5 | 541 | 3.21 | 2.01 | 6.61 | 2.01 | >2001 |
| D67N, K70R, M184V, T215F, K219Q | 25 (0.6) | 19 | 41.1 | 7.71 | 1.51 | 1.11 | 6.51 | 1.71 | >2001 |
| D67N, K70R, K219Q | 24 (0.6) | 24 | 41.7 | 262 | 1.82 | 1.82 | 0.92 | 1.43 | |
| D67N, K70R | 24 (0.6) | 20 | 42.3 | 172 | 0.92 | 1.52 | 1.02 | 0.82 | 1.42 |
| L74V | 21 (0.5) | 19 | 42.8 | 1.11 | 0.91 | 1.81 | 2.61 | ||
| M41L, M184V, T215F | 21 (0.5) | 17 | 43.3 | 4.63 | 1.63 | 5.83 | 2.03 | >2003 | |
| M41L, V118I, L210W, T215Y | 21 (0.5) | 16 | 43.8 | 131 | 1.91 | 2.01 | 1.11 | 1.42 | |
| M41L, D67N, L210W, T215Y | 18 (0.4) | 18 | 44.3 | 1,0003 | 2.43 | 5.03 | 4.53 | 1.63 | 4.03 |
| T69N, K70R | 18 (0.4) | 17 | 44.7 | 7.02 | 0.82 | 1.32 | 0.82 | 0.82 | 0.82 |
| M41L, E44D, D67N, V118I, L210W, T215Y | 18 (0.4) | 17 | 45.1 | 1191 | 3.61 | 2.31 | 1.61 | 4.41 | |
| M41L, L74V, M184V, T215Y | 18 (0.4) | 17 | 45.6 | 0.71 | 1.22 | 6.31 | 1.82 | >2002 | |
| T69N | 18 (0.4) | 16 | 46.0 | 0.52 | 0.92 | 0.82 | 1.12 | 1.12 | 2.32 |
a
Of 4,183 persons, 3,550 had 4,089 mutant sequences with 1,120 different NRTI mutation patterns. The top 30 patterns accounted for 46.0% of the mutant sequences.
b
Median susceptibility results (n-fold) for isolates with matching patterns of mutations. The subscript is the number of samples with available susceptibility results. Results above the PhenoSense reduced susceptibility cutoff (≥1.9 for ZDV, ≥1.7 for D4T, ≥1.4 for TDF, ≥4.5 for ABC, ≥1.7 for DDI, and ≥3.5 for 3TC [fold]) are shown in bold. Abbreviations: ZDV, zidovudine; D4T, stavudine; TDF, tenofovir; ABC, abacavir; DDI, didanosine; 3TC, lamivudine.